EA201591403A1 - Спиролактамные модуляторы рецептора nmda и их применение - Google Patents

Спиролактамные модуляторы рецептора nmda и их применение

Info

Publication number
EA201591403A1
EA201591403A1 EA201591403A EA201591403A EA201591403A1 EA 201591403 A1 EA201591403 A1 EA 201591403A1 EA 201591403 A EA201591403 A EA 201591403A EA 201591403 A EA201591403 A EA 201591403A EA 201591403 A1 EA201591403 A1 EA 201591403A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nmda receptor
spirolactam
application
receptor modulators
compounds
Prior art date
Application number
EA201591403A
Other languages
English (en)
Other versions
EA031905B1 (ru
Inventor
Джон А. Лоу, III
М. Амин Кхан
Original Assignee
Аптиникс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50071822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591403(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аптиникс Инк. filed Critical Аптиникс Инк.
Publication of EA201591403A1 publication Critical patent/EA201591403A1/ru
Publication of EA031905B1 publication Critical patent/EA031905B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

Описаны соединения, обладающие повышенной эффективностью модулирования активности рецептора NMDA. Указанные соединения предусмотрены для применения при лечении патологических состояний, таких как депрессия и родственные расстройства. Описаны также перорально доступные композиции и другие фармацевтически приемлемые формы доставки соединений, включая внутривенные композиции.
EA201591403A 2013-01-29 2014-01-29 Спиролактамные модуляторы рецептора nmda и их применение EA031905B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361757934P 2013-01-29 2013-01-29
PCT/US2014/013623 WO2014120786A1 (en) 2013-01-29 2014-01-29 Spiro-lactam nmda receptor modulators and uses thereof

Publications (2)

Publication Number Publication Date
EA201591403A1 true EA201591403A1 (ru) 2017-05-31
EA031905B1 EA031905B1 (ru) 2019-03-29

Family

ID=50071822

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591403A EA031905B1 (ru) 2013-01-29 2014-01-29 Спиролактамные модуляторы рецептора nmda и их применение

Country Status (16)

Country Link
US (2) US9758525B2 (ru)
EP (1) EP2951184A1 (ru)
JP (1) JP6419087B2 (ru)
KR (1) KR20150110787A (ru)
CN (1) CN105229010A (ru)
AU (1) AU2014212487C1 (ru)
BR (1) BR112015018092A2 (ru)
CA (1) CA2898863A1 (ru)
CL (1) CL2015002123A1 (ru)
EA (1) EA031905B1 (ru)
IL (1) IL240166A0 (ru)
MX (1) MX2015009773A (ru)
PE (1) PE20151437A1 (ru)
PH (1) PH12015501595B1 (ru)
SG (1) SG11201505934XA (ru)
WO (1) WO2014120786A1 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
SI2753632T1 (sl) 2011-09-08 2023-08-31 Sage Therapeutics, Inc. Nevroaktivni steroidi, njihovi sestavki in uporaba
MX2015009785A (es) 2013-01-29 2016-04-04 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
WO2014120789A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
ES2734405T3 (es) * 2013-01-29 2019-12-05 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
PT3461834T (pt) 2013-03-13 2021-09-10 Sage Therapeutics Inc Esteroides neuroativos
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
KR20170065637A (ko) * 2014-10-07 2017-06-13 세이지 테라퓨틱스, 인크. 신경활성 화합물 및 그의 사용 방법
CN104326960A (zh) * 2014-11-04 2015-02-04 崇州合瑞科技有限公司 一种制备Boc-L-脯氨酸的方法
CN104326943A (zh) * 2014-11-04 2015-02-04 崇州合瑞科技有限公司 一种制备Boc-L-丝氨酸的方法
SG10202002655VA (en) 2015-07-06 2020-05-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
LT3319611T (lt) 2015-07-06 2021-05-10 Sage Therapeutics, Inc. Oksisteroliai ir jų naudojimo būdai
EP3411369A1 (en) * 2016-02-01 2018-12-12 Lupin Limited Process for the preparation of ledipasvir and intermediates thereof
CA3019146C (en) 2016-04-01 2024-03-26 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN105924402A (zh) * 2016-05-06 2016-09-07 蚌埠中实化学技术有限公司 一种2-胺基甲基嘧啶盐酸盐的制备方法
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP6590226B2 (ja) * 2016-05-11 2019-10-16 株式会社シード探索研究所 オキサアジリジン化合物およびその製造方法
SG11201810280YA (en) * 2016-05-19 2018-12-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
RS62222B1 (sr) 2016-07-07 2021-09-30 Sage Therapeutics Inc 24-hidroksisteroli supstituisani na poziciji 11 za upotrebu u lečenju stanja povezanih sa nmda
JP2019527232A (ja) * 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
SG11201900443VA (en) * 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2017306158B2 (en) * 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
CN110023323A (zh) 2016-09-30 2019-07-16 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
MX2019004679A (es) 2016-10-18 2019-10-15 Sage Therapeutics Inc Oxisteroles y metodos de uso de los mismos.
EP4252848A3 (en) 2016-10-18 2023-11-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN107602436A (zh) * 2017-09-29 2018-01-19 新发药业有限公司 一种n‑取代‑l‑焦谷氨酸酯的绿色制备方法
PE20211455A1 (es) * 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2019152685A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and methods of using same
TW202110852A (zh) * 2019-06-24 2021-03-16 美商諾雷克斯股份有限公司 用於產生二氮雜螺內醯胺化合物之方法及中間物
AU2020304001A1 (en) * 2019-06-24 2022-01-27 Naurex Inc. Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
WO1992007561A1 (fr) 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Preparation d'un gel anti-inflammatoire et analgesique
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
SK166798A3 (en) 1996-06-07 1999-07-12 Zeneca Ltd Peptide derivatives, process for their preparation, pharmaceutical composition them containing, and their use
US5959075A (en) 1996-08-02 1999-09-28 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
JP2003521247A (ja) 2000-02-01 2003-07-15 エージーワイ セラピューティクス インコーポレーテッド Ｎｍｄａ受容体のプロテインチロシンホスファターゼとの相互作用
AU2001268467A1 (en) 2000-06-14 2001-12-24 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
EP1296999A2 (en) 2000-06-22 2003-04-02 NYXIS NeuroTherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
AU2002236608A1 (en) 2000-12-14 2002-06-24 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
WO2002072005A2 (en) 2001-03-07 2002-09-19 University Of Utah Research Foundation Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
WO2004005293A2 (en) 2002-07-05 2004-01-15 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2005014797A2 (en) 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2006034196A1 (en) 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
ATE520404T1 (de) 2005-03-24 2011-09-15 Univ Emory Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron
WO2007025141A2 (en) 2005-08-26 2007-03-01 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
CA2663502A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
JP6078211B2 (ja) 2008-02-20 2017-02-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 自閉症および自閉症の表現型に関連する遺伝子変化ならびに自閉症の診断および治療に対するその使用方法
KR101647520B1 (ko) 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
ES2750825T3 (es) * 2008-09-19 2020-03-27 Concert Pharmaceuticals Inc Compuestos de morfinano deuterados
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
WO2011003064A2 (en) 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
DK2485751T3 (da) 2009-10-05 2014-08-18 Univ Northwestern GLYX-13 til anvendelse i en fremgangsmåde til behandling af upåvirkelig depression
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
MX2012009388A (es) * 2010-02-11 2012-10-01 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato estabilizado de estructura secundaria y sus usos.
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20200043534A (ko) 2011-04-27 2020-04-27 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
EP2723506B1 (en) 2011-06-27 2017-02-15 Koninklijke Philips N.V. Ultrasound transducer assembly and method of manufacturing the same
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
WO2014120789A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2015009785A (es) 2013-01-29 2016-04-04 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
ES2734405T3 (es) * 2013-01-29 2019-12-05 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof

Also Published As

Publication number Publication date
EP2951184A1 (en) 2015-12-09
AU2014212487A1 (en) 2015-07-30
BR112015018092A2 (pt) 2017-07-18
CL2015002123A1 (es) 2015-12-04
US20150368253A1 (en) 2015-12-24
CA2898863A1 (en) 2014-08-07
SG11201505934XA (en) 2015-09-29
PH12015501595A1 (en) 2015-10-19
PH12015501595B1 (en) 2015-10-19
EA031905B1 (ru) 2019-03-29
KR20150110787A (ko) 2015-10-02
MX2015009773A (es) 2016-08-05
CN105229010A (zh) 2016-01-06
US9758525B2 (en) 2017-09-12
JP6419087B2 (ja) 2018-11-07
IL240166A0 (en) 2015-09-24
US20180179217A1 (en) 2018-06-28
PE20151437A1 (es) 2015-10-10
AU2014212487C1 (en) 2018-10-25
JP2016506960A (ja) 2016-03-07
AU2014212487B2 (en) 2018-04-19
WO2014120786A1 (en) 2014-08-07
US10273239B2 (en) 2019-04-30

Similar Documents

Publication Publication Date Title
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201591405A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201591402A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
EA201591401A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
CL2015000942A1 (es) Compuestos de benceno sustituido.
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
NZ737399A (en) Ccr2 modulators
EA201590881A1 (ru) Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201491610A1 (ru) Модуляторы x рецепторов печени
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU